SCHEMBL4934703

SCHEMBL4934703

CCCn1ccc2cc(C(=O)O)ccc21

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PLA2G4A P47712 2/20 0.55
▸ HCAR3 P49019 3/20 0.50
▸ ALDH1A1 P00352 1/20 0.50
▸ HPGD P15428 1/20 0.50
▸ PLG P00747 1/20 0.50
▸ PLAU P00749 1/20 0.50
▸ TUBB4A P04350 2/20 0.47
▸ TUBB P07437 2/20 0.47
▸ TUBA3C P0DPH7 2/20 0.47
▸ TUBA1B P68363 2/20 0.47
▸ TUBA4A P68366 2/20 0.47
▸ TUBB4B P68371 2/20 0.47
▸ TUBB3 Q13509 2/20 0.47
▸ TUBB2A Q13885 2/20 0.47
▸ TUBB8 Q3ZCM7 2/20 0.47
▸ TUBA3E Q6PEY2 2/20 0.47
▸ TUBA1A Q71U36 2/20 0.47
▸ TUBA1C Q9BQE3 2/20 0.47
▸ TUBB6 Q9BUF5 2/20 0.47
▸ TUBB2B Q9BVA1 2/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1749895 0.91 PLA2G4A (0.59) PLA2G4AHCAR3PLGPLAUNR1H2
SCHEMBL846081 0.90 PLA2G4A (0.61) PLA2G4AHCAR3PLGPLAUNR1H2
SCHEMBL7340362 0.88 PLA2G4A (0.63) PLA2G4AHCAR3PLGPLAUNR1H2
SCHEMBL5981752 0.88 MCL1 (0.57) PLA2G4AHCAR3ALDH1A1HPGDMCL1
SCHEMBL5387474 0.87 TUBB4A (0.59) PLA2G4AHCAR3ALDH1A1PLGPLAU
SCHEMBL1664063 0.86 PLG (0.51) PLA2G4APLGPLAUTUBB4ATUBB
SCHEMBL16440983 0.85 PLG (0.48) PLA2G4AALDH1A1HPGDPLGPLAU
SCHEMBL6752488 0.84 HTR2C (0.55) PLA2G4AALDH1A1PLGPLAURAPGEF4
SCHEMBL1809906 0.84 HCAR3 (0.53) PLA2G4AHCAR3ALDH1A1PLGPLAU
SCHEMBL9033792 0.83 PLG (0.44) PLA2G4APLGPLAUTUBB4ATUBB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2022128851-A1 DIHYDROFUROPYRIDINE DERIVATIVES AS RHO- KINASE INHIBITORS CHIESI FARMACEUTICI S.P.A. (IT) 2022-06-23 — — WO disclosed
US-8394828-B2 Quinoline-derived amide modulators of vanilloid VR1 receptor JANSSEN PHARMACEUTICA, NV (BE) 2013-03-12 — — US disclosed
CN-102358741-A Azepinoindole derivatives as pharmaceutical agents EXELIXIS INC 2012-02-22 — — CN disclosed
US-20080300236-A1 QUINOLINE-DERIVED AMIDE MODULATORS OF VANILLOID VR1 RECEPTOR CODD ELLEN 2008-12-04 — — US disclosed
CN-1914207-A Aza * -indoline derivatives as medicaments EXELIXIS INC (US) 2007-02-14 — — CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080300236-A1 QUINOLINE-DERIVED AMIDE MODULATORS OF VANILLOID VR1 RECEPTOR TRPV1, OPRL1, TRPV2 PLA2G4A 1276/4885HCAR3 21/4885ALDH1A1 1216/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback